Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Лираглутид и сердечно-сосудистые исходы при сахарном диабете 2 типа
2016-06-13
SCID: 54.1/uucmsqj4
Discuss with AI
LEADER trialcardiovascular outcomesliraglutidemajor adverse cardiovascular events (MACE)type 2 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were performed for the prespecified exploratory outcomes. RESULTS: A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority). Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P=0.007). The rate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02). The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group. The most common adverse events leading to the discontinuation of liraglutide were gastrointestinal events. The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group. CONCLUSIONS: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).
Key Findings
1
All-cause mortality was lower with liraglutide than placebo (8.2% vs. 9.6%; HR 0.85; 95% CI 0.74–0.97; P=0.02).
2
Gastrointestinal adverse events were the most common reason for discontinuation of liraglutide; pancreatitis incidence was nonsignificantly lower with liraglutide than placebo.
3
In a double-blind randomized trial of 9340 high cardiovascular–risk type 2 diabetes patients, liraglutide reduced the primary composite outcome (cardiovascular death, nonfatal MI, or nonfatal stroke) versus placebo (13.0% vs. 14.9%; HR 0.87; 95% CI 0.78–0.97).
4
Liraglutide significantly lowered death from cardiovascular causes compared with placebo (4.7% vs. 6.0%; HR 0.78; 95% CI 0.66–0.93; P=0.007).
5
Rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were lower with liraglutide than placebo but differences were not statistically significant.
Research Object
Patients with type 2 diabetes and high cardiovascular risk enrolled in a randomized double-blind trial of liraglutide versus placebo
Research Subject
Effect of add-on liraglutide versus placebo on major cardiovascular outcomes (first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), all-cause mortality, and related safety events
Publication Details
Publication Date
2016-06-13
Journal
Publisher
ISSN
Cited by
7626
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by18
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes2016
2023 ESC Guidelines for the management of acute coronary syndromes2023
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2020
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD2019
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2018
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association2021
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022
Glucagon-like peptide 1 (GLP-1)2019
The Discovery and Development of Liraglutide and Semaglutide2019
Safety of Semaglutide2021
Endothelial Glycocalyx2022
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes2025
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement2025
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health2025
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care2025
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications2026
Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study2018